formic-valeric anhydride | 115956-35-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: formic-valeric anhydride
• 英文别名: formylvalerate；Ketomethylvalerate；formyl pentanoate
• CAS: 115956-35-9
• 化学式: C₆H₁₀O₃
• 分子量: 130.144
• InChiKey: GXOGLXKLKOVKEA-UHFFFAOYSA-N

物化性质

• 沸点：
  171.9±23.0 °C(Predicted)
• 密度：
  1.013±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  formic-valeric anhydride 在 甲酸 、 环己醇 作用下， 以 邻二氯苯 为溶剂， 生成 戊酸酐
  参考文献：
  名称：

  Kinetics of alcoholysis of valeric anhydride by cyclohexanol in the presence of formic acid

  摘要：

  Kinetics of the reaction proceeding at the industrial process of cyclohexane oxidation are studied by the model reaction of the alcoholysis of valeric anhydride by cyclohexanol in the presence of formic acid.

  DOI：

  10.1134/s1070427209030227
• 作为产物：
  描述：

  戊酸酐 、 formic anhydride 在 甲酸 、 环己醇 作用下， 以 邻二氯苯 为溶剂， 生成 formic-valeric anhydride
  参考文献：
  名称：

  Kinetics of alcoholysis of valeric anhydride by cyclohexanol in the presence of formic acid

  摘要：

  Kinetics of the reaction proceeding at the industrial process of cyclohexane oxidation are studied by the model reaction of the alcoholysis of valeric anhydride by cyclohexanol in the presence of formic acid.

  DOI：

  10.1134/s1070427209030227

文献信息

• [EN] 1,1'-DIADAMANTYL CARBOXYLIC ACIDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE<br/>[FR] ACIDES 1,1'-DIADAMANTYL CARBOXYLIQUES, MÉDICAMENTS CONTENANT DE TELS COMPOSÉS ET APPLICATION ASSOCIÉE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010010174A1

  公开（公告）日：2010-01-28

  The present invention relates to compounds defined by formula (I) wherein the group R is defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases.

  本发明涉及由式（I）定义的化合物，其中基团R如权利要求1中所定义，具有有价值的药理活性。特别是这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以受到该酶抑制影响的疾病，如代谢性疾病。
• [EN] COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS<br/>[FR] COMPOSÉS DESTINÉS AU TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：WELLSTAT THERAPEUTICS CORP

  公开号：WO2009091732A1

  公开（公告）日：2009-07-23

  Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. The agent is a compound of Formula (I): wherein m is 0, 1, 2, 3, 4, 5, 6, 7 or 8; R1 is hydrogen or alkyl having from 1 to 3 carbon atoms; and R2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms. A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, hydroxy, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono- substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; Alternatively, the agent can be a pharmaceutically acceptable salt of the compound of Formula (I).

  本发明涉及一种用于治疗各种代谢性疾病的药物，例如胰岛素抵抗综合征、糖尿病、多囊卵巢综合征、高脂血症、脂肪肝病、消瘦、肥胖症、动脉粥样硬化和动脉硬化。该药物是公式（I）的化合物：其中m为0、1、2、3、4、5、6、7或8；R1为氢或具有1至3个碳原子的烷基；R2为氢、卤素、具有1至3个碳原子的烷基或具有1至3个碳原子的烷氧基。A为苯基，未取代或被1或2个选自以下基团的基团取代：卤素、羟基、具有1或2个碳原子的烷基、全氟甲基、具有1或2个碳原子的烷氧基和全氟甲氧基；或具有3至6个环碳原子的环烷基，其中环烷基未取代或一个或两个环碳原子独立地被甲基或乙基单取代；或具有1或2个选自N、S和O的环杂原子的5或6元杂环芳基，且杂环芳基通过环碳原子与公式I的剩余部分共价结合。或者，该药物可以是公式（I）的药学上可接受的盐。
• [EN] PROCESS FOR THE PREPARATION OF FORMYLVALERIC ACID AND ADIPIC ACID<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ACIDE FORMYLAVÉRIQUE ET D'ACIDE ADIPIQUE
  申请人：DSM IP ASSETS BV

  公开号：WO2014111446A1

  公开（公告）日：2014-07-24

  The invention relates to a process for the production of 5-formylvaleric acid and adipic acid or esters thereof from an isomeric mixture of pentenoic acid or esters thereof said mixture comprising at least 4-pentenoic acid or esters thereof, and further comprising 3-pentenoic acid and/or 2-pentenoic acid or esters thereof, theprocess comprising: (a) subjecting the isomeric mixture of pentenoic acid to a hydroformylation reaction comprising a hydroformylation catalyst which is non-isomerizing towards the pentenoic acid or esters thereof to obtain a mixture comprising 5-formylvaleric acid or esters thereof and further comprising 3-pentenoic acid and/or 2-pentenoic acid, or esters thereof; (b) separating the 3-pentenoic acid and/or 2-pentenoic acid, or esters thereof from the 5-formylvaleric acid or esters thereof; (c) subjecting the separated pentenoic acids or esters thereof to a carbonylation reaction comprising an isomerizing carbonylation catalyst to obtain adipic acid or esters thereof; (d) optionally isolating the adipic acid or ester thereof; and (e) optionally isolating the separated 5-formylvaleric acid or esters thereof. The process allows for efficient production of two different intermediates for producing polyamide using a single process, with good selectivity, little waste, in an economically efficient fashion. The process is very suitable to use an isomeric pentenoic acid mixture obtained from valerolactone, and can be used to produce renewable polyamide intermediates using a single process.

  本发明涉及一种从戊烯酸异构体混合物或其酯中生产5-甲酰基戊二酸和己二酸或其酯的工艺，所述混合物包括至少4-戊烯酸或其酯，并进一步包括3-戊烯酸和/或2-戊烯酸或其酯，该工艺包括：(a)将戊烯酸异构体混合物经过羰基化催化剂催化的羰基化反应，该催化剂对戊烯酸或其酯不进行异构化，以得到包括5-甲酰基戊二酸或其酯和进一步包括3-戊烯酸和/或2-戊烯酸或其酯的混合物；(b)将3-戊烯酸和/或2-戊烯酸或其酯与5-甲酰基戊二酸或其酯分离；(c)将分离的戊烯酸或其酯经过异构化羰基化催化剂催化的羰基化反应，以得到己二酸或其酯；(d)可选择性地分离己二酸或其酯；以及(e)可选择性地分离分离的5-甲酰基戊二酸或其酯。该工艺允许使用单一工艺高效生产用于制造聚酰胺的两种不同的中间体，具有良好的选择性，少量废料，经济高效。该工艺非常适合使用从缩酮酸获得的异构戊烯酸混合物，并可用于使用单一工艺生产可再生聚酰胺中间体。
• 1,1'-Diadamantyl carboxylic acids, medicaments containing such compounds and their use
  申请人：Eckhardt Matthias

  公开号：US20110269736A1

  公开（公告）日：2011-11-03

  The present invention relates to compounds defined by formula (I) wherein the group R is defined as in claim 1 , possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases.

  本发明涉及具有有价值的药理活性的公式（I）所定义的化合物，其中R基团如权利要求1所定义。特别地，这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以通过抑制该酶而受到影响的疾病，例如代谢性疾病。
• Halopyridones
  申请人：ZENECA INC.

  公开号：EP0246669A2

  公开（公告）日：1987-11-25

  A 3- or 4-halo-2-pyridone compound of the formula: in which X⁴ is halogen (preferably bromine or chlorine) is a useful chemical intermediate in the synthesis of 2-halo-­5-methylpyridines themselves useful in the preparation of, for example, 4-(5-halomethyl-2-pyridyloxy)phenoxy herbicides.

  式中 X⁴ 为卤素（最好是溴或氯）的 3-或 4-卤代-2-吡啶酮化合物是合成 2-卤代-5-甲基吡啶的有用化学中间体，可用于制备 4-（5-卤甲基-2-吡啶氧基）苯氧基除草剂等。